Phys Clinical Cases · oncological
Immune Checkpoint Inhibitor Toxicity — DCE Clinical Case
DCE long-case and short-case clinical station for immune checkpoint inhibitor toxicity: comprehensive patient assessment, presentation and discussion for a 64-year-old man on combination ipilimumab-nivolumab for metastatic melanoma who develops multisystem immune-related adverse events (grade 3 colitis, hypophysitis with secondary adrenal insufficiency, grade 2 hepatitis, and a grade 2 maculopapular rash), including the CTCAE grading framework, the steroid-dose ladder, second-line infliximab and mycophenolate, the permanent-discontinuation decision, and a focused general-examination routine with the troponin-for-chest-pain rule.
On this page
Study tools
Target exams
The patient
Mr K is a 64-year-old retired engineer who was diagnosed with metastatic melanoma (BRAF wild-type, PD-L1 positive) eight months ago. He commenced combination ipilimumab and nivolumab four months ago and has tolerated the first three cycles well, with a partial response on the most recent CT. Three weeks ago he developed loose stools, which have progressed to eight bloody bowel motions per day with mucus, abdominal cramps and urgency. Over the same period he has noticed a diffuse itchy rash over his trunk, profound fatigue, and dizziness on standing. He has lost 4 kg. He is otherwise well, takes no regular medications, and has no prior autoimmune disease. [1]
Examination findings
- General: alert but fatigued, mildly jaundiced. Diffuse maculopapular rash over the trunk, confluent, involving approximately 25 per cent of body surface area. No mucosal involvement.
- Vital signs: heart rate 108, blood pressure 104/62 lying and 88/54 standing, respiratory rate 20, oxygen saturation 96 per cent on room air, temperature 37.4.
- Abdomen: diffuse tenderness, no peritonism, bowel sounds hyperactive, no organomegaly.
- Respiratory: fine bibasal crackles.
- Cardiovascular: no murmur, no rub, no raised JVP.
- Neurological: no ptosis, no fatigability, no focal deficit, GCS 15.
- Endocrine: no thyroid bruit, no hyperpigmentation; confrontation visual fields show a mild bitemporal restriction. [1]
Investigations
- Sodium 126, potassium 5.1, urea 9.2, creatinine 140 (baseline 88).
- ALT 260, AST 210, ALP 180, bilirubin 58, INR 1.3, albumin 28.
- Haemoglobin 112, white cells 14.6, eosinophils 0.4, platelets 230.
- TSH 16.4 mU/L (high), free T4 6 pmol/L (low), random cortisol 70 nmol/L (low), ACTH 5 ng/L (low), FSH low, LH low, testosterone low, prolactin mildly raised.
- Troponin normal. ECG normal sinus rhythm.
- Stool culture, C. difficile toxin, ova cysts and parasites sent, results pending.
- Hepatitis A, B, C and E serology, CMV and EBV PCR, autoimmune markers — pending.
- Abdominal ultrasound with Doppler — pending. [1]
References9ShowHide
- [1]Halene S, Gao Y, Hahn K, et al. Serum response factor is an essential transcription factor in megakaryocytic maturation Blood, 2010.PMID 20525922
- [2]Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med, 2012.PMID 22658127
- [3]Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol, 2017.PMID 28881921
- [4]Brahmer JR, Lacchetti C, Thompson JA, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol, 2018.PMID 29442540
- [5]Postow MA, Sidlow R, Hellmann MD Immune-Related Adverse Events Associated with Immune Checkpoint Blockade N Engl J Med, 2018.PMID 29320654
- [6]Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors J Am Coll Cardiol, 2018.PMID 29567210
- [7]Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis JAMA Oncol, 2018.PMID 30242316
- [8]Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials J Clin Oncol, 2017.PMID 28841387
- [9]Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis Cancer Immunol Immunother, 2017.PMID 28204866